GuidelineEuropean journal of nuclear medicine and molecular imaging2021
EANM guideline on the role of 2-[
Guideline in European journal of nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 3 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- Head-to-head comparison of fibroblast activation protein inhibitors (FAPI) radiopharmaceuticals and [European journal of nuclear medicine and molecular imaging · 2025Pooled it
- Joint EANM-SNMMI guideline on the role of 2-[European journal of nuclear medicine and molecular imaging · 2024Guideline
- Meta-analysis of the diagnostic value ofFrontiers in oncology · 2022Pooled it
- Value of anQuantitative imaging in medicine and surgery · 2026Article
- Comparative analysis ofEuropean journal of nuclear medicine and molecular imaging · 2026Article
- 2[18F]-FDG-PET/CT and 2[18F]-FDG-PET/MRI in primary staging of epithelial ovarian cancer - an early interim analysis of a prospective clinical trial.Annals of medicine and surgery (2012) · 2026Article
- The role of PET/CT in preoperative decision-making for secondary cytoreduction in recurrent ovarian cancer.BMC cancer · 2026Article
- Additive value of whole abdomen FDG PET/MRI to standard whole body PET/CT for detection of peritoneal recurrence of ovarian cancer.Journal of ovarian research · 2026Article
- Multimodal AI in high-grade serous ovarian cancer: integrated prediction and clinical decision-making.Frontiers in oncology · 2026Review
- Predictive value of 18F-FDG-PET/CT for pathologic complete response (pCR) of lesions after neoadjuvant chemotherapy in advanced ovarian cancer.World journal of surgical oncology · 2025Article
- PET/CT Volumetric Parameters as Predictors of the Peritoneal Cancer Index in Advanced Ovarian Cancer Patients.Diagnostics (Basel, Switzerland) · 2025Article
- FAPI radiopharmaceuticals in nuclear oncology and theranostics of solid tumours: are we nearer to surrounding the hallmarks of cancer?Annals of nuclear medicine · 2025Review
- Prognostic Value of PretreatmentCancers · 2025Article
- LAT1-specific PET radiotracers: Development and clinical experiences of a new class of cancer-specific radiopharmaceuticals.Theranostics · 2025Review
- Dual-receptor PET imaging of ovarian cancer using aAmerican journal of nuclear medicine and molecular imaging · 2025Article
- Anatomy, Imaging, and Surgical Treatment of Thoracic Lymphadenopathies in Advanced Epithelial Ovarian Cancer.Cancers · 2024Review
- Predicting Complete Cytoreduction with Preoperative [Diagnostics (Basel, Switzerland) · 2024Review
- Article
- Guardians of precision: advancing radiation protection, safety, and quality systems in nuclear medicine.European journal of nuclear medicine and molecular imaging · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In most patients with ovarian carcinoma, the diagnosis is reached when the disease is long past the initial stages, presenting already an advanced stage, and they usually have a very bad prognosis. Cytoreductive or debulking surgical procedures, platinum-based chemotherapy and targeted agents are key therapeutic elements. However, around 7 out of 10 patients present recurrent disease within 36 months from the initial diagnosis. The metastatic spread in ovarian cancer follows three pathways: contiguous dissemination across the peritoneum, dissemination through the lymphatic drainage and, although less importantly in this case, through the bloodstream. Radiological imaging, including ultrasound, CT and MRI, are the main imaging techniques in which management decisions are supported, CT being considered the best available technique for presurgical evaluation and staging purposes. Regarding 2-[
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.